Is Repligen (RGEN) Fully Priced After Its $1B Notes Deal?

Repligen has climbed to a recent close of US$172.62 after a mixed run that combines a 14.7% gain over the past year with a far weaker 5 year record. With that backdrop and new financing on the table, the real question is whether the current share price lines up with the cash the business is expected to generate.

• Over 5 years the stock is down 38.4%. This puts the spotlight firmly on whether today’s valuation can still be explained by the stream of cash flows ahead.
• The new US$1.0b convertible senior notes, along with planned share repurchases and potential acquisitions, can reshape Repligen’s future cash flows by altering both financing costs and how much capital is available for growth investments.
• What if you looked at Repligen through its sales instead? See why Repligen's 13.7x P/S tells a different valuation story.

The issue now is whether Repligen’s current market price is adequately supported by the cash flows implied by a Discounted Cash Flow (DCF) view.

If you are weighing Repligen against other opportunities built around cash generation, it can help to compare it with companies surfaced by a simple set of quality filters such as 32 high quality undervalued stocks

Where Does Repligen Sit on Cash Flow?

The Discounted Cash Flow (DCF) approach here projects the cash Repligen could return to shareholders and compares it with the US$172.62 share price. On the cash side, the business produced about US$97.6 million of free cash flow over the last twelve months, while the model assumes that annual free cash flow keeps building over the coming decade rather than shrinking.

Those projections reach several hundred million dollars a year by the early 2030s, so the DCF outcome implies an intrinsic value broadly in line with where Repligen trades today. The new US$1.0b of low coupon convertible senior notes adds another layer, because the extra capital for buybacks and potential acquisitions can change how that future cash flow per share ultimately looks. Because this fresh financing is already public, the market seems to be treating it as part of the story behind the current valuation. Find out what Repligen could be worth using our Discounted Cash Flow (DCF) estimate.

The Repligen Narrative: What Would Justify Today's Price?

Narratives for Repligen pick up where the DCF puzzle leaves off by spelling out which paths for growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today’s price. Each Narrative ties its number to a clear view of how Repligen’s expansion potential, profitability profile and key uncertainties might evolve, giving you a concrete reference point to revisit as fresh information comes through.

One of the top narratives on Repligen: roughly fairly valued

This Narrative is the bearish analyst Narrative on Simply Wall St, built on the most pessimistic analyst price target and forecasts, not one person's view.

"The main factor that has to go right is that Repligen successfully executes on the BioLife integration, Asia Pacific expansion, and a higher margin mix of proteins, analytics, and services..."

Discover why this Narrative puts Repligen at roughly fairly valued.

Before acting on Repligen's valuation, look at who is steering the ship

Price and cash flows only tell part of the story, because the people allocating Repligen's capital and the way their rewards are structured can heavily influence how those numbers evolve over time. See who runs Repligen and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com